Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2021.12414

MMR-0-0-12414

Articles

ADAM10 attenuates the development of abdominal aortic aneurysms in a mouse model

Qiu

Renfeng

1 2 Chen

Shuxiao

1 Gao

Peixian

1 3 Luo

Kun

1 Feng

Xuedong

3 Yuan

Hai

1 3 Wu

Xuejun

1 3 Li

Gang

1 3

1Department of Vascular Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, P.R. China 2Department of Vascular Surgery, Shouguang People's Hospital of Shandong, Jinan, Shandong 262700, P.R. China 3Department of Vascular Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China

Correspondence to: Professor Gang Li or Professor Xuejun Wu, Department of Vascular Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong 250021, P.R. China, E-mail: ligangdoctor627@163.com, E-mail: sdwuxuejun@163.com

11 2021

06 09 2021

24 5

774

05022021 23072021

2021

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

An abdominal aortic aneurysm (AAA) is a life-threatening disease associated with a high mortality rate. At present, surgery or minimally invasive interventions are used in clinical treatment, especially for small aneurysms. However, the benefits of surgical repair are not obvious, and AAA ruptures can be prevented by aneurysm therapy to inhibit the growth of small aneurysms. Therefore, evaluating effective drugs to treat small AAAs is urgently required. Chronic inflammation is the main pathological feature of aneurysmal tissues. The aim of the present study was to investigate the protective role and underlying mechanism of ADAM metallopeptidase domain 10 (ADAM10). In the present study, a mouse model of AAA was established via porcine pancreatic elastase perfusion for 5 min per day for 14 days. ADAM10 (6 mg/kg) was injected intraperitoneally following 3 days of porcine pancreatic elastase perfusion in the ADAM10 group and the treatment continued for 10 days. The maximum inner luminal diameters of the infrarenal abdominal aortas were measured using an animal ultrasound system. The levels of high mobility group box 1 (HMGB1) and soluble receptor for advanced glycosylation end products in serum samples were measured by ELISA. Hematoxylin and eosin and elastin van Gieson staining were performed to observe morphology, integrity of the elastin layers and elastin degradation. CD68 expression was detected by immunohistochemical staining. Reverse transcription-quantitative PCR and western blotting were used for detection of mRNA and protein levels. The gelatinolytic activities of MMP-2 and MMP-9 were quantified via gelatin zymography analysis. These results showed that ADAM10 inhibited HMGB1/RAGE/NF-κB signaling and MMP activity in the pathogenesis of pancreatic elastase-induced AAA, which provide insight into the molecular mechanism of AAA and suggested that ADAM10 may be a potential therapeutic target for AAA.

ADAM metalloprotease domain 10 high mobility group box 1 receptor for advanced glycosylation end products NF-κB abdominal aortic aneurysm

National Natural Science Foundation of Chinahttp://dx.doi.org/10.13039/501100001809

81800409

81670435

Major Research and Development Program of Shandong

2017GSF218074

This research was funded by National Natural Science Foundation of China (grant nos. 81800409 and 81670435) and the Major Research and Development Program of Shandong (grant no. 2017GSF218074).

Introduction

An abdominal aortic aneurysm (AAA) is diagnosed if the diameter of an artery is >30 mm or if it has increased by >50% compared with the adjacent normal aorta (1). The mortality rate of patients with an AAA rupture is 65–85%; currently, surgery or minimally invasive interventions are used for clinical treatment (2). However, randomized trials have reported that, although selective repair of AAAs can prevent rupture of the aneurysms and related deaths, it causes more perioperative deaths than any other common types of surgery or vascular surgery (3). Especially for small aneurysms, the benefits of surgical repair are not obvious, and an AAA rupture is likely to be prevented by aneurysm therapy to inhibit the growth of small aneurysms (4). Therefore, examining effective drugs to treat small AAAs is urgently required.

Chronic inflammation is the main pathological feature in aneurysmal tissues, involving the infiltration of inflammatory cells, elastic fiber degradation of the extracellular matrix (ECM), neovascularization and apoptosis, dysfunction of vascular smooth muscle cells and the release of a range of proteolytic enzymes, such as MMPs, oxidation-derived free radicals, cytokines and related products (5). Macrophages are the dominant factor in the production of MMPs during the inflammation of the media and adventitia. These MMPs cause the degradation of the ECM (6).

Receptor for advanced glycosylation end products (RAGE) is a cell-surface multiligand receptor of the immunoglobulin superfamily (7). As an important regulator of chronic and sustained inflammation, RAGE serves a key role in the development and progression of pathological states, such as cardiovascular disease, diabetic vascular complications, Alzheimer's disease (AD), cancer and a range of inflammatory diseases (8,9). RAGE exists as a full-length isoform (fl-RAGE) and a soluble isoform (sRAGE). fl-RAGE consists of extracellular domains, a short transmembrane helix and a cytosolic C-terminal short tail. The cytosolic short tail domain is critical, and is responsible for transducing downstream signaling from the extracellular space to the intracellular space (10). sRAGE is one of the truncated forms of RAGE and is found in the serum in humans. As an endogenous competitor of RAGE, increased levels of sRAGE serve a critical role within the modulatory network of the ligand/RAGE axis and acts to alleviate the inflammatory response. As a biomarker of RAGE-mediated pathogenesis, sRAGE can reflect RAGE activity in the opposite direction (11). Furthermore, ectodomain shedding by proteolysis of RAGE is a means of sRAGE production.

High mobility group box 1 (HMGB1), one of the ligands of RAGE and a proinflammatory factor, is an evolutionarily highly conserved nuclear, nonhistone DNA-binding protein that exerts a proinflammatory role in a series of pathologies by regulating the release of inflammatory cytokines, activating macrophages and increasing vascular permeability (12). HMGB1 is involved in the pathogenesis of inflammatory conditions via its interactions with pivotal transmembrane receptors, including RAGE and Toll-like receptor-4 (13,14). Extracellular hyperexpression of HMGB1 has been documented in various diseases, such as cardiovascular disease, septic shock, rheumatoid arthritis, atherosclerosis, traumatic brain injury and ischemia/reperfusion injury (15–17). After binding to membrane receptors, HMGB1 activates downstream NF-κB and further stimulates the expression of related inflammatory factors, such as oxidative stress and proinflammatory cytokines, which has been observed in AAAs (18).

ADAM metallopeptidase domain 10 (ADAM10) is one of the most closely studied members of the ADAM family, which has been shown to participate in the inflammatory response, and it is a target for the treatment of inflammatory diseases (19). As a membrane-anchored protease, ADAM10-mediated shedding is essential for numerous biological processes, such as cell migration, proliferation and (20,21). ADAM10 is also responsible for RAGE cleavage, and binding to its ligand HMGB1 promotes RAGE shedding (22). Moreover, targeting of ADAM10 is a therapeutic strategy for the treatment of AD and prion disease (23), but its role in AAAs remains unknown.

Therefore, in the present study, we hypothesized that ADAM10 may attenuate the inflammatory progression of AAAs by inhibiting HMGB1/RAGE/NF-κB signaling. The current study examined the effect of ADAM10 on the expression levels of HMGB1 and RAGE, and the activation of NF-κB in an experimental model of AAAs in C57BL/6 mice.

Materials and methods <sec> <title>Animal groups

A total of 21 male C57BL/6 wild-type mice (age, 8–12 weeks; weight, 20–26 g) were purchased from the Experimental Animal Center of Shandong University (Jinan, China). The mice were randomly divided into the following groups (n=7 per group): i) Sham-operated (Sham) group; ii) AAA model (AAA) group; and iii) ADAM10-treated (ADAM10) group. Mice were housed at 20–25°C and a humidity of 40–70% with a 12:12 h light-dark cycle. Water and food were given ad libitum and were provided by the Experimental Center of Shandong Provincial Hospital Affiliated with Shandong University. This study was performed according to the Care and Use of Laboratory Animals guidelines (24). The experimental protocols were approved by the Ethical Review Board of Shandong University (approval no. 2018-015). The animal experiments were performed between 01/2019 and 12/2019.

Establishment of the AAA model and administration of ADAM10

The AAA model was established as described previously (25). Briefly, mice were anesthetized via 2.5% isoflurane inhalation. A para-abdominal median incision was made to expose the lower abdominal aorta to the bifurcation of the abdominal aorta, and a 10-mm segment of the infrarenal abdominal aorta was exposed. Subsequently, 30 µl porcine pancreatic elastase (1.5 U/ml; cat. no. E1250; Sigma-Aldrich; Merck KGaA) was perfused intraluminally for 5 min via a PPE-10 catheter that had been inserted into the aorta. PBS was used as a control in the Sham group. ADAM10 (6 mg/kg; cat. no. 936-AD; R&D Systems, Inc.) was injected intraperitoneally after 3 days of porcine pancreatic elastase perfusion in the ADAM10 group and the treatment continued for 10 days. At the end of the study, the mice were euthanized under CO₂ exposure (flow rate of CO₂, 2 l/min; air displacement rate, 20%/min). Blood was collected after mouse euthanasia via cardiac puncture. Blood samples were separated via centrifugation at 3,000 × g at 4°C for 10 min and stored at −80°C. The aortas were embedded in Tissue-Tek O.C.T. compound at −80°C or stored at −80°C for protein and reverse transcription-quantitative (RT-q) PCR detection.

Measurements of the abdominal aortic diameter

The maximum inner luminal diameters of the infrarenal abdominal aortas were measured using an animal ultrasound system (FUJIFILM VisualSonics, Inc.). Measurements and analysis of dilation were carried out on days 3, 7 and 14 after AAA induction by two experienced operators who did not know their group assignment. AAA was defined as dilatation >50% of the average diameter of the aorta.

ELISA examination

The levels of HMGB1 and sRAGE in the serum samples were measured using ELISA kits (HMGB1, cat. no. CSB-E08225, Cusabio Technology LLC; sRAGE, cat. no. MRG00, R&D Systems, Inc.) according to the manufacturer's instructions. Sample diluent (100 µl) and serum (100 µl) were added to the wells and incubated at 37°C for 2 h. Subsequently, biotin-labeled antibody working fluid (100 µl; 1X antibody) was added to each well and incubated at 37°C for 1 h. Then, the plate was washed three times with 0.01 M PBS. A total of 100 µl substrate solution was added and incubated at room temperature for 1 h. TMB color developing agent (90 µl) was added to each well and incubated at 37°C for 30 min in the dark, and then 50 µl termination solution was added. The optical density value was measured using a ThermoMultiskan GO microplate reader (1510-01981; Thermo Fisher Scientific, Inc.) at 450 nm.

H&E and Elastin van Gieson (EVG) staining

The aortic specimens were fixed in 4% paraformaldehyde for 24 h at room temperature, then cut into 5-µm serial sections using a freezing microtome. H&E and EVG staining were performed following a standard protocol. The sections were stained with hematoxylin for 3 min and eosin solution for 15 sec at room temperature. The sections were stained with Weigerts Resorcin Fuchsin solution for 45 min and Van Gieson solutions for 5 min at room temperature for EVG staining. The integrity of the elastin layers and elastin degradation were observed by light microscopy (BX3-CBH; OLYMPUS cellSens Standard 1.16; Olympus Corporation; magnification, ×50 and ×200).

Immunohistochemical staining

The aortic specimens were fixed in 4% paraformaldehyde for 24 h at room temperature, and then after washing and dehydration they were embedded by optimal cutting temperature compound and stored in −80°C. The sections were cut into 5-µm serial sections by a freezing microtome as previously described (26). The sections were incubated with primary polyclonal antibodies against CD68 (1:400; cat. no. ab125212; Abcam) at 4°C overnight and blocked with goat serum (1:10; cat. no. ZLI-9021; ZSGB-BIO) for 30 min at room temperature. The sections were incubated with secondary HRP-goat anti-rabbit IgG antibodies for 30 min at room temperature by the rabbit polymer detection system (1X; cat. no. PV-6001; ZSGB-BIO). The sections were then stained with DAB reagent (1X) for 3 min at room temperature. Stained sections were observed by light microscopy (BX3-CBH; OLYMPUS cellSens Standard 1.16; Olympus Corporation).

RT-qPCR analysis

Total RNA was extracted from the abdominal aorta tissue using TRIzol^® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. cDNA was synthesized from 1 µg total RNA according to the manufacturer's protocol by PrimeScript RT reagent kit gDNAEraser (cat. no. RR047A; Takara Bio, Inc.) in a 20 µl reaction volume. RT-qPCR was performed with 2 µl cDNA and gene-specific primers in a final 20 µl reaction system. The forward and reverse primers designed by Takara Bio, Inc. are shown in Table I. Amplification was performed using a SYBR Premix Ex Taq kit (Takara Bio, Inc.), and the thermocycling conditions were as follows: Initial denaturation at 95°C for 30 sec, followed by 45 cycles of 95°C for 3 sec and 60°C for 30 sec. The relative mRNA expression was assessed using the 2^−∆∆Cq method (27). The relative expression of the target gene was normalized to that of β-actin.

Western blot analysis

Mouse aortas were harvested for protein extraction by RIPA buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) and a BCA protein concentration kit (cat. no. P0010; Beyotime Institute of Biotechnology) was used for protein determination. A total of 30 µg protein extract was loaded per lane and separated by 10% SDS-PAGE and then electrotransferred to PVDF membranes (MilliporeSigma), which were blocked with 5% skimmed milk in PBS-0.05% Tween-20 (PBST) at room temperature for 1 h. Next, primary antibodies against HMGB1 (1:1,000; cat. no. ab18256; Abcam), RAGE (1:1,000; cat. no. ab3611; Abcam), phosphorylated (p)-NF-κB p65 (Ser536; 93H1; 1:1,000; cat. no. 3033; Cell Signaling Technology, Inc.), NF-κB p65 (1:1,000; cat. no. ab16502; Abcam) and GAPDH (1:2,000; cat. no. ab181602; Abcam) were applied at 4°C overnight. The membranes were washed three times, for 10 min each time, in PBST (0.1% Tween-20). The appropriate horseradish peroxidase-conjugated secondary antibodies were applied at room temperature for 2 h including Goat Anti-Rabbit (1:3,000; cat. no. ZB-5305; ZSGB-BIO) and Rabbit Anti-Mouse IgG H&L (1:2,000; cat. no. ZB-2301; ZSGB-BIO). The bands were visualized using ECL assays (Thermo Fisher Scientific, Inc.) and assessed via semi-quantification of the optical density with Multi Gauge v3.2 software (FUJIFILM Wako Pure Chemical Corporation). GAPDH was used as an internal reference.

Gelatin zymography analysis

Tissue extracts were isolated according to the procedures described for the western blot analysis. Proteins were extracted from mouse aorta using RIPA buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) and a BCA protein concentration kit (cat. no. P0010; Beyotime Institute of Biotechnology) was used for protein determination. The procedures used were conducted as described previously (28). The gelatinolytic activities of MMP-2 and MMP-9 were quantified via densitometric analysis by Azure Biosystems capture software v1.6 (29).

Statistical analysis

All the experiments were repeated three times. Data were analyzed using SPSS 19.0 software (IBM Corp.) and are presented as the mean ± SEM. The significant differences in mean values among groups was examined via one-way ANOVA followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>ADAM10 reduces pathological injury to the abdominal aortic wall in a mouse AAA model

A total of 2 weeks after elastase perfusion, a severe AAA developed with significant dilation of the infrarenal aortic lumen in the AAA groups. Ultrasound examination revealed that the largest diameters of the aorta were significantly increased compared with those in the Sham groups, while they were significantly decreased in the ADAM10 groups (Fig. 1A and B).

H&E staining identified that ADAM10 decreased the injury to the abdominal aortic wall. A normal abdominal aortic wall was shown in sham group (Fig. 1C-a and d). The significant injury in elastic laminae presented with flattening, fragmentation and degeneration in the medial layer, accompanied with the thickened and remodeled aortic adventitia in the AAA groups (Fig. 1C-b and e). ADAM10 significantly reduced elastin degradation in the aortic media, and the elastic lamellae partially recovered its wavy structures, thereby maintaining the integrity of the aortic intima in the ADAM10 groups (Fig. 1C-c and f). EVA staining revealed the normal form of elastin (Fig. 1D-a and d). Moreover, elastin in the aortic adventitia was thickened (Fig. 1D-b and e), which was reduced by ADAM10 (Fig. 1D-c and f).

ADAM10 reduces the inflammatory response of the abdominal aortic wall in a mouse AAA model

The inflammatory responses in the experimental model was examined via histopathologic analysis. Immunohistochemical staining demonstrated that there was only a few CD68⁺ inflammatory cells in the normal aortic wall (Fig. 2A-a and d), while the inflammatory cells accumulated and infiltrated into the aortic wall in the AAA groups (Fig. 2A-b and e), and this phenomenon was attenuated in the ADAM10 groups compared with the AAA groups (Fig. 2A-c and f). The increased number of CD68⁺ macrophages in the aortic wall in the AAA groups increased significantly compared with sham groups, which was significantly attenuated in the ADAM10 groups (Fig. 2B). Furthermore, ADAM10 decreased the expression levels of the proinflammatory mediators, including IL-1β, TNF-α and monocyte chemoattractant protein-1, in the aortic wall of the AAA as shown via RT-qPCR analysis (Fig. 2C).

ADAM10 inhibits the expression of MMPs

RT-qPCR analysis demonstrated that the mRNA expression levels of MMP-2 and MMP-9 were significantly increased in the AAA groups, but were significantly downregulated in the ADAM10 groups on day 14 (Fig. 3A).

Gelatin zymography examination revealed that the activities of MMP-2 and MMP-9 were notably increased in the AAA groups and were significantly downregulated in the aneurysmal wall in the ADAM10 groups on day 14 (Fig. 3B).

ADAM10 reduces serum HMGB1 levels, while increasing serum sRAGE levels in a mouse AAA model

Serum HMGB1 and sRAGE levels changed in an opposite manner in the AAA group. In the AAA group, serum HMGB1 was significantly increased as detected via ELISA, and this effect was reduced in the ADAM10 group (Fig. 4A). Furthermore, a lower level of serum sRAGE was detected in the AAA group, while a significant increase in serum sRAGE levels was observed in the ADAM10 group (Fig. 4B).

ADAM10 decreases aortic wall HMGB1, RAGE and NF-κB expression in the AAA model

The mRNA and protein expression levels of HMGB1, RAGE and NF-κB were detected in the aneurysm walls via RT-qPCR and western blotting, respectively. The RT-qPCR results demonstrated that the mRNA expression level of HMGB1 was higher in the AAA group, which was significantly downregulated by ADAM10. Moreover, the mRNA expression level of RAGE was higher in the AAA group, which was significantly reduced by ADAM10. It was also found that the mRNA expression level of NF-κB was higher in the AAA group, which was decreased significantly by ADAM10 (Fig. 5A). The western blotting results were consistent with those of the RT-qPCR. The protein expression levels of HMGB1 and RAGE, and the ratio of the phosphorylation of NF-κB p65/NF-κB p65 were higher in the AAA group, and were significantly decreased in the ADAM10 group (Fig. 5B).

ADAM10 inhibits the progression rate of small AAAs in a mouse model

Ultrasound examination showed the largest diameters of the aorta on day 0, 3, 7 and 14 after infusion (Fig. 6A). In the ADAM10-treated group, after 4 days, the growth curve of the AAA began to alter, showing a downward trend, and the maximum aortic diameter was significantly decreased after 3 and 10 days of continuous treatment (Fig. 6B). This indicated that ADAM10 treatment was able to significantly limit the progression rate of small AAAs.

Discussion

In the present study, to test the hypothesis that the inflammatory mediator ADAM10 is an important factor in the pathophysiology of AAA, a mouse AAA model was established by incubating the infrarenal aorta with pancreatic elastase. The results demonstrated that ADAM10 inhibited HMGB1/RAGE/NF-κB signaling and MMP activity in the pathogenesis of pancreatic elastase-induced AAA.

AAA is described as a degenerative and dilated disease of the abdominal aorta and small, asymptomatic AAAs currently have no favorable therapeutic options, although it has been demonstrated in animal and clinical models that inflammatory processes have an important role in the pathophysiology of AAA (5). Macrophages accumulating and infiltrating the aneurysmal wall cause tissue injury, producing and responding to inflammatory mediators, and they release proteases, such as Cathepsin S protein and MMPs, resulting in ECM remodeling during the formation of AAAs (30). There are numerous drugs that have been tested in animals and clinical trials with the goal of inhibiting the development of AAAs, such as statins (31), β-adrenoceptor antagonists (32), renin-angiotensin system inhibitors (33) and doxycycline (34). However, at present, there is no established drug therapy that can efficiently inhibit the development of AAAs or reverse small AAAs (35).

The present study selected a mouse AAA model induced by pancreatic elastase perfusion, the pathological changes of which are considered to be the closest to the pathophysiological changes of human AAAs (36). The aneurysm wall has obvious inflammatory responses (37), which is consistent with the purpose of the current study. This experimental mouse model has been widely accepted and applied to study the pathophysiology of AAA (38). To examine its therapeutic effects, ADAM10 was intraperitoneally injected into the mice on the first day after the AAA was induced and the treatment continued for 10 days. The present results suggested that ADAM10 can significantly alleviate the development of AAAs, which was reflected by the observation that ADAM10 inhibited the dilatation of the infrarenal aorta. After ADAM10 treatment, the flattening, fragmentation and degeneration of the aortic intimal elastic laminae and remodeling of the aortic adventitia were significantly relieved compared with those of the AAA group. All of these results suggested that ADAM10 had an obvious preventive effect on the progression of AAA, which provides a basis for its clinical transformation and its use for the inhibition of AAAs. The mechanism may be mediated via downregulation of HMGB/RAGE/NF-κB signaling.

HMGB-1, a typical damage-associated molecular pattern protein released from various cells, such as macrophages, smooth muscle cells, endothelial cells, cardiomyocytes, epithelial cells and neurons (39), serves a pivotal role in multiple cardiovascular diseases, inflammatory and infectious disorders (40,41). It performs its biological function by combining with receptors, including RAGE (42). In the present experiment, the expression of HMGB1 was increased in the circulation at both the transcriptional and translational levels in AAA model mice compared with the Sham group, and HMGB1 has been shown to activate and amplify inflammatory effector mechanisms (43). RAGE is the cellular target receptor for HMGB1, and the binding of HMGB1 to the RAGE pathway is associated with activating and modulating the inflammatory pathological process (44); therefore, the HMGB1/RAGE signaling axis may play a critical role in the development of AAAs.

RAGE has been shown to be involved in the pathological process of chronic inflammatory diseases, such as atherosclerosis, AD, inflammatory bowel disease, rheumatoid arthritis, amyloidosis and late diabetic vascular complications (45). In general, the extracellular domain is critical and is responsible for binding to the specific ligand, and the cytosolic tail domain is essential for transmitting RAGE signaling from the cell surface to the downstream targets involved in the progression of inflammatory responses (46). Ligand binding of fl-RAGE can activate and amplify inflammatory states (47) as sRAGE lacks the transmembrane and C-terminal cytoplasmic domain of fl-RAGE, and thus, is unable to mediate intracellular signaling, acting as a ‘decoy’ receptor. sRAGE competitively combines with the same ligand and prevents its binding to fl-RAGE, without conducting signals to the intracellular site to activate downstream signaling cascades (22,48). Previous animal studies indicated that treatment of diabetic RAGE^−/−/apoE^−/− mice suppressed inflammation of the blood vessels and oxidative stress, as well as attenuated atherosclerosis development (49). ADAM10-mediated ectodomain shedding of the extracellular domain of RAGE simultaneously generates sRAGE, and serves a role in inhibiting the RAGE-mediated signaling pathway and alleviating inflammation (50). In support of this, in the current study, RAGE expression was increased in the AAA model group and was decreased in the ADAM10 group. Increasing serum sRAGE suggests that RAGE participates in the pathological development of AAA. Additionally, ADAM10 inhibited RAGE activity via ectodomain cleavage of functional fl-RAGE to produce more inactive sRAGE, acting as a decoy, competitively binding ligands and inhibiting its deleterious effects. The present finding was also consistent with previous studies examining inflammatory, autoimmune and infectious diseases (51–53).

NF-κB is a family implicated in numerous diseases, ranging from cancer to inflammatory and immune disorders (54). Inflammation serves an important role in contributing to the development of AAAs. Importantly, NF-κB also regulates inflammation (55). HMGB1/RAGE signaling stimulates a positive feedback loop, induces multiple downstream signaling pathways, such as the stress-activated protein kinase/JNK, cell division cycle 42/Rac, p38 MAPK and ERK1/2, and activates the downstream proinflammatory transcription factor NF-κB, which subsequently induces the production of inflammatory factors (55,56). Thus, the HMGB1/RAGE/NF-κB axis may be involved in the pathophysiology of AAA.

In the present study, typical AAA formation was observed in the AAA group, and an associated pathway (HMGB1/RAGE/NF-κB) was activated, which was consistent with previous studies (55–59). The diameter of the AAA was significantly smaller and the HMGB1/RAGE/NF-κB pathway was inactivated in the ADAM10 group. Therefore, it was suggested that ADAM10 inhibited RAGE activity by cleaving fl-RAGE to non-functional sRAGE as a decoy receptor that neutralizes circulating ligands, thereby affecting HMGB1 binding with RAGE, and ultimately inhibiting the activity of the HMGB1/RAGE/NF-κB signaling axis and reducing inflammation in the AAA wall. ADAM10 decreased inflammatory factor induced aggregation by macrophages, T-cells and B-cells, and further reduced MMP-2 and MMP-9 production, thus alleviating the development of AAA. However, the results in the current study should be interpreted with caution since they may not completely reflect changes that are occurring on a functional level.

In conclusion, the present study demonstrated that ADAM10 alleviated the development of AAA in an intraluminal elastase-induced mouse AAA model and reversed small AAAs by inhibiting aortic inflammation via the HMGB1/RAGE/NF-κB pathway to further inhibit MMP activity. This study provides insight into the molecular mechanism and a potential therapeutic strategy for AAA.

Acknowledgements

Not applicable.

Funding

This research was funded by National Natural Science Foundation of China (grant nos. 81800409 and 81670435) and the Major Research and Development Program of Shandong (grant no. 2017GSF218074).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

RQ, SC and GL were responsible for designing the study, collecting the data, performing the statistical analysis and drafting the manuscript. RQ, PG, KL, XF and HY collected the data, performed the statistical analysis and conducted the literature search. XW and GL supervised the project, helped to design the study, analyzed the data and wrote the manuscript. All authors confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Animal Ethics Committee of Shandong University (approval no. 2018-015).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Johnston

Rutherford

Tilson

Shah

Hollier

Stanley

Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery

J Vasc Surg134524581991

10.1067/mva.1991.26737

1999868

Sampson

Norman

Fowkes

Aboyans

Yanna

Song

Harrell

JrForouzanfar

Naghavi

Denenberg

McDermott

Global and regional burden of aortic dissection and aneurysms: Mortality trends in 21 world regions, 1990 to 2010

Glob Heart9171180.e102014

10.1016/j.gheart.2013.12.010

25432126

Ghaferi

Birkmeyer

Dimick

Variation in hospital mortality associated with inpatient surgery

N Engl J Med361136813752009

10.1056/NEJMsa0903048

19797283

Shang

Ran

Qiao

Liu

Tanshinone IIA attenuates elastase-induced AAA in rats via inhibition of MyD88-dependent TLR-4 signaling

Vasa4339462014

10.1024/0301-1526/a000326

24429329

Golledge

Abdominal aortic aneurysm: Update on pathogenesis and medical treatments

Nat Rev Cardiol162252422019

10.1038/s41569-018-0114-9

30443031

Raffort

Lareyre

Clément

Hassen-Khodja

Chinetti

Mallat

Monocytes and macrophages in abdominal aortic aneurysm

Nat Rev Cardiol144574712017

10.1038/nrcardio.2017.52

28406184

Neeper

Schmidt

Brett

Yan

Wang

Pan

Elliston

Stern

Shaw

Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins

J Biol Chem26714998150041992

10.1016/S0021-9258(18)42138-2

1378843

Kierdorf

Fritz

RAGE regulation and signaling in inflammation and beyond

J Leukoc Biol9455682013

10.1189/jlb.1012519

23543766

Piperi

Adamopoulos

Dalagiorgou

Diamanti-Kandarakis

Papavassiliou

Crosstalk between advanced glycation and endoplasmic reticulum stress: Emerging therapeutic targeting for metabolic diseases

J Clin Endocrinol Metab97223122422012

10.1210/jc.2011-3408

22508704

Huttunen

Fages

Rauvala

Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways

J Biol Chem27419919199241999

10.1074/jbc.274.28.19919

10391939

Santilli

Vazzana

Bucciarelli

Davì

Soluble forms of RAGE in human diseases: Clinical and therapeutical implications

Curr Med Chem169409522009

10.2174/092986709787581888

19275604

van Zoelen

Yang

Florquin

Meijers

Akira

Arnold

Nawroth

Bierhaus

Tracey

van der Poll

Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo

Shock312802842009

10.1097/SHK.0b013e318186262d

19218854

Paudel

Angelopoulou

Piperi

Balasubramaniam

VRMT

Othman

Shaikh

Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling

Eur J Pharmacol8581724872019

10.1016/j.ejphar.2019.172487

31229535

Andersson

Yang

Harris

High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells

Semin Immunol3840482018

10.1016/j.smim.2018.02.011

29530410

Oozawa

Mori

Kanke

Takahashi

Liu

Tomono

Asanuma

Miyazaki

Nishibori

Sano

Effects of HMGB1 on ischemia-reperfusion injury in the rat heart

Circ J72117811842008

10.1253/circj.72.1178

18577832

Andrassy

Volz

Igwe

Funke

Eichberger

Kaya

Buss

Autschbach

Pleger

Lukic

High-mobility group box-1 in ischemia-reperfusion injury of the heart

Circulation117321632262008

10.1161/CIRCULATIONAHA.108.769331

18574060

Hamada

Torikai

Kuwazuru

Tanaka

Horai

Fukuda

Yamada

Nagayama

Hashiguchi

Sunahara

Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis

Arthritis Rheum58267526852008

10.1002/art.23729

18759291

Golledge

Muller

Daugherty

Norman

Abdominal aortic aneurysm: Pathogenesis and implications for management

Arterioscler Thromb Vasc Biol26260526132006

10.1161/01.ATV.0000245819.32762.cb

16973970

Saftig

Reiss

The ‘A Disintegrin And Metalloproteases’ ADAM10 and ADAM17: Novel drug targets with therapeutic potential?

Eur J Cell Biol905275352011

10.1016/j.ejcb.2010.11.005

21194787

Donners

Wolfs

Olieslagers

Mohammadi-Motahhari

Tchaikovski

Heeneman

van Buul

Caolo

Molin

Post

Waltenberger

A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis

Arterioscler Thromb Vasc Biol30218821952010

10.1161/ATVBAHA.110.213124

20814017

Maretzky

Reiss

Ludwig

Buchholz

Scholz

Proksch

de Strooper

Hartmann

Saftig

ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation

Proc Natl Acad Sci USA102918291872005

10.1073/pnas.0500918102

15958533

Raucci

Cugusi

Antonelli

Barabino

Monti

Bierhaus

Reiss

Saftig

Bianchi

A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)

FASEB J22371637272008

10.1096/fj.08-109033

18603587

Jiao

Yao

Zhang

Hao

Sun

Yuan

Jing

Wang

Role of MicroRNA-103a targeting ADAM10 in abdominal aortic aneurysm

Biomed Res Int201796458742017

10.1155/2017/9645874

28357407

National Research Council (US) Institute for Laboratory Animal Research

Guide for the care and use of laboratory animals

Washington (DC)

National Academies Press

1996

Anidjar

Salzmann

Gentric

Lagneau

Camilleri

Michel

Elastase-induced experimental aneurysms in rats

Circulation829739811990

10.1161/01.CIR.82.3.973

2144219

Zhang

Kent

Yamanouchi

Zhang

Kato

Tsai

Nowygrod

Schmidt

Liu

Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm

Ann Surg2504164232009

10.1097/SLA.0b013e3181b41a18

19652591

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Yang

Yuan

Liu

Jin

Cold-inducible RNA-binding protein plays a central role in the pathogenesis of abdominal aortic aneurysm in a murine experimental model

Surgery159165416672016

10.1016/j.surg.2016.01.007

26936526

Snoek-van Beurden

Von den Hoff

Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors

Biotechniques3873832005

10.2144/05381RV01

15679089

Murray

Wynn

Protective and pathogenic functions of macrophage subsets

Nat Rev Immunol117237372011

10.1038/nri3073

21997792

Shiraya

Miyake

Aoki

Yoshikazu

Ohgi

Nishimura

Ogihara

Morishita

Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration

Atherosclerosis20234402009

10.1016/j.atherosclerosis.2008.03.020

18482727

Lindholt

Henneberg

Juul

Fasting

Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms

Int Angiol1852571999

10392481

Morris

Cunningham

Ahimastos

Kingwell

Pappas

Bourke

Reid

Stijnen

Dalman

Aalami

TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial

Trials162742015

10.1186/s13063-015-0793-z

26081587

Meijer

Stijnen

Wasser

Hamming

van Bockel

Lindeman

Pharmaceutical Aneurysm Stabilisation Trial Study Group

Doxycycline for stabilization of abdominal aortic aneurysms: A randomized trial

Ann Intern Med1598158232013

10.7326/0003-4819-159-12-201312170-00007

24490266

Kokje

Hamming

Lindeman

Editor's Choice-pharmaceutical management of small abdominal aortic aneurysms: A systematic review of the clinical evidence

Eur J Vasc Endovasc Surg507027132015

10.1016/j.ejvs.2015.08.010

26482507

Busch

Holm

Wagner

Ergün

Rosenfeld

Otto

Baur

Kellersmann

Lorenz

Extra- and intraluminal elastase induce morphologically distinct abdominal aortic aneurysms in mice and thus represent specific subtypes of human disease

J Vasc Res5349572016

10.1159/000447263

27532120

Busch

Chernogubova

Jin

Meurer

Eckstein

Kim

Maegdefessel

Four surgical modifications to the classic elastase perfusion aneurysm model enable haemodynamic alterations and extended elastase perfusion

Eur J Vasc Endovasc Surg561021092018

10.1016/j.ejvs.2018.03.018

29703523

Johnston

Salmon

Ailawadi

Upchurch

Aromatase is required for female abdominal aortic aneurysm protection

J Vasc Surg61156574.e1-e42015

10.1016/j.jvs.2014.01.032

24582702

Pei

Wei

Kang

Wang

Xie

Emerging role of high mobility group Box-1 in thrombosis-related diseases

Cell Physiol Biochem47131913372018

10.1159/000490818

29940562

Bae

Role of high mobility group box 1 in inflammatory disease: Focus on sepsis

Arch Pharm Res35151115232012

10.1007/s12272-012-0901-5

23054707

Ding

Yang

High mobility group box-1 and cardiovascular diseases

Saudi Med J314864892010

20464035

van Beijnum

Buurman

Griffioen

Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1)

Angiogenesis1191992008

10.1007/s10456-008-9093-5

18264787

Hreggvidsdottir

Ostberg

Wähämaa

Schierbeck

Aveberger

Klevenvall

Palmblad

Ottosson

Andersson

Harris

The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation

J Leukoc Biol866556622009

10.1189/jlb.0908548

19564572

Sims

Rowe

Rietdijk

Herbst

Coyle

HMGB1 and RAGE in inflammation and cancer

Annu Rev Immunol283673882010

10.1146/annurev.immunol.021908.132603

20192808

Bierhaus

Humpert

Morcos

Wendt

Chavakis

Arnold

Stern

Nawroth

Understanding RAGE, the receptor for advanced glycation end products

J Mol Med (Berl)838768862005

10.1007/s00109-005-0688-7

16133426

Dattilo

Fritz

Leclerc

Kooi

Heizmann

Chazin

The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units

Biochemistry46695769702007

10.1021/bi7003735

17508727

Basta

Lazzerini

Massaro

Simoncini

Tanganelli

Kislinger

Stern

Schmidt

De Caterina

Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses

Circulation1058168222002

10.1161/hc0702.104183

11854121

Sung

Chung

Kim

Chang

Lee

Jung

Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism

Tohoku J Exp Med23059662013

10.1620/tjem.230.59

23748365

Soro-Paavonen

Watson

Paavonen

Koitka

Calkin

Barit

Coughlan

Drew

Lancaster

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

Diabetes57246124692008

10.2337/db07-1808

18511846

Zhang

Bukulin

Kojro

Roth

Metz

Fahrenholz

Nawroth

Bierhaus

Postina

Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases

J Biol Chem28335507355162008

10.1074/jbc.M806948200

18952609

Detzen

Cheng

Chen

Papapanou

Lalla

Soluble forms of the receptor for advanced glycation endproducts (RAGE) in periodontitis

Sci Rep981702019

10.1038/s41598-019-44608-2

31160611

Ramasamy

Schmidt

Schmidt, Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging

Biochem Pharmacol79137913862010

10.1016/j.bcp.2010.01.013

20096667

Lee

Park

Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: Potential biomarkers for diagnosis and therapeutic targets for human renal diseases

Genomics Inform112242292013

10.5808/GI.2013.11.4.224

24465234

Baud

Karin

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

Nat Rev Drug Discov833402009

10.1038/nrd2781

19116625

Nakashima

Aoki

Miyake

Kawasaki

Iwai

Oishi

Kataoka

Ohgi

Ogihara

Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors

Circulation1091321382004

10.1161/01.CIR.0000105725.61763.A2

14662712

Chen

Chan

Chiang

Wang

Yang

Lan

Chao

Tsai

Yang

Liu

Advanced glycation end-products induced VEGF production and inflammatory responses in human synoviocytes via RAGE-NF-κB pathway activation

J Orthop Res347918002016

10.1002/jor.23083

26497299

Medeiros

Frasnelli

Bastos Ade

Orrico

Rossa

Modulation of cell proliferation, survival and gene expression by RAGE and TLR signaling in cells of the innate and adaptive immune response: Role of p38 MAPK and NF-KB

J Appl Oral Sci221851932014

10.1590/1678-775720130593

25025559

Lappas

Permezel

Rice

Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-kappaB and extracellular signal-regulated kinase 1/2

J Endocrinol1932692772007

10.1677/JOE-06-0081

17470518

Hofmann

Drury

Taguchi

Avila

Kambham

Bierhaus

Nawroth

RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides

Cell978899011999

10.1016/S0092-8674(00)80801-6

10399917

Figure 1.

ADAM10 reduces pathological injury to the abdominal aortic wall in a mouse AAA model. (A) Representative ultrasonographic images of aortas from the different groups before infusion and on day 14 after infusion. The blue bar indicates the diameter of the aorta. (B) Quantitative analysis of the diameters of the aortas on days 0, 3, 7 and 14 after infusion in different groups. (Ca) A normal abdominal aortic wall was shown in sham group in low magnification. (Cb) The injury in elastic laminae and aortic adventitia was shown in the AAA groups in low magnification. (Cc) ADAM10 significantly reduced the injury in the aortic wall in the ADAM10 groups in low magnification. (Cd) A normal abdominal aortic wall was shown in sham groups in high magnification. (Ce) The injury in elastic laminae and aortic adventitia was shown in the AAA groups in high magnification. (Cf) ADAM10 significantly reduced the injury in the aortic wall in the ADAM10 groups in high magnification. (Da) EVA staining showed the normal form of elastin in sham groups in low magnification. (Db) EVA staining showed the thickened elastin in the aortic adventitia in AAA groups in low magnification. (Dc) EVA staining showed reduced elastin in ADAM10 groups in low magnification. (Dd) EVA staining showed the normal form of elastin in sham groups in high magnification. (De) EVA staining showed the thickened elastin in the aortic adventitia in AAA groups in high magnification. (Df) EVA staining showed reduced elastin in ADAM10 groups in high magnification. Scale bars, 200 µm. All the data are expressed as the mean ± SEM; n=7 per group. ^#P<0.05 vs. sham group; *P<0.05 vs. AAA group. Sham group, the mouse received intraaortic infusions of saline alone; AAA group, the mouse treatment with intraaortic elastase infusion; ADAM10 group, the mouse received ADAM10 treatment after intraaortic elastase infusion. EVG, elastica van Gieson; AAA, abdominal aortic aneurysm; ADAM10, ADAM metallopeptidase domain 10.

Figure 2.

ADAM10 reduces the inflammatory response of the abdominal aortic wall in a mouse AAA model. (A) Representative micrographs of immunohistochemical staining of cluster of differentiation CD68⁺ macrophages in different groups. (Aa) CD68+ inflammatory cells in the normal aortic wall in sham groups in low magnification. (Ab) The CD68+ inflammatory cells accumulated and infiltrated into the aortic wall in the AAA groups in low magnification. (Ac) The infiltration of CD68+ inflammatory cells was attenuated in ADAM10 groups in low magnification. (Ad) CD68+ inflammatory cells in the normal aortic wall in sham groups in low magnification. (Ae) The CD68+ inflammatory cells accumulated and infiltrated into the aortic wall in the AAA groups in low magnification. (Af) The infiltration of CD68+ inflammatory cells was attenuated in ADAM10 groups in low magnification. Scale bars, 200 µm. (B) Quantitative analysis of the scores of CD68⁺ cells. (C) Reverse transcription-quantitative PCR analysis showing the expression levels of IL-1β, TNF-α and MCP-1 in the different groups. ^#P<0.05 vs. sham group; *P<0.05 vs. AAA group. The relative mRNA levels of TNF-α, IL-1β and MCP-1 were normalized to those of β-actin. MCP-1, monocyte chemoattractant protein-1; AAA, abdominal aortic aneurysm; ADAM10, ADAM metallopeptidase domain 10.

Figure 3.

ADAM10 inhibits the expression of MMPs. (A) Reverse transcription-quantitative PCR analysis showing the mRNA expression levels of MMP-2 and MMP-9 on day 14. (B) Gelatin zymography examination showing the activities of MMP-2 and MMP-9 on day 14. ^#P<0.05 vs. sham group; *P<0.05 vs. AAA group. AAA, abdominal aortic aneurysm; ADAM10, ADAM metallopeptidase domain 10.

Figure 4.

ADAM10 reduces serum HMGB1 levels, while increasing serum sRAGE levels in a mouse AAA model. ELISA showing the levels of serum (A) HMGB1 and (B) sRAGE. ^#P<0.05 vs. sham group; *P<0.05 vs. AAA group. AAA, abdominal aortic aneurysm; ADAM10, ADAM metallopeptidase domain 10; sRAGE, soluble receptor for advanced glycosylation end products; HMGB1, high mobility group box 1.

Figure 5.

ADAM10 reduces aortic wall HMGB1, RAGE and NF-κB expression in the AAA model. (A) Reverse transcription-quantitative PCR analysis showing the mRNA expression levels of HMGB1 and RAGE on day 14. (B) Representative western blotting images and summarized data showing the protein expression levels of HMGB1 and RAGE, and the ratio of NF-κB p-p65/NF-κB p65 on the day 14. ^#P<0.05 vs. sham group; *P<0.05 vs. AAA group. AAA, abdominal aortic aneurysm; ADAM10, ADAM metallopeptidase domain 10; RAGE, receptor for advanced glycosylation end products; HMGB1, high mobility group box 1; p-, phosphorylated.

Figure 6.

ADAM10 inhibits the progression rate of small AAAs in a mouse model. (A) Representative ultrasonographic images of aortas from the different groups on day 0, 3, 7 and 14 after infusion. The blue bar indicates the diameter of the aorta. (B) Quantitative analysis of the diameter curve of the aortas on days 0, 3, 7 and 14 after infusion in different groups. ^#P<0.05 vs. AAA group. AAA, abdominal aortic aneurysm; ADAM10, ADAM metallopeptidase domain 10; PPE, porcine pancreatic elastase.

Table I.

Primers for reverse transcription-quantitative PCR analysis.

Gene	Sequences
RAGE	Forward: 5′-GCTGTAGCTGGTGGTCAGAACA-3′
	Reverse: 5′-CCCCTTACAGCTTAGCACAAGTG-3′
HMGB1	Forward: 5′-ATGGGCAAAGGAGATCCTA-3′
	Reverse: 5′-ATTCATCATCATCATCTTCT-3′
NF-κB	Forward: 5′-GCATTCTGACCTTGCCTATCT-3′
	Reverse: 5′-CTCCAGTCTCCGAGTGAAGC-3′
MMP-2	Forward: 5′-CCCTGGTGGCTGGAGGCTCT-3′
	Reverse: 5′-AACGGGGTCCCACGTCCCAA-3′
MMP-9	Forward: 5′-GCATCCGAGCAAGAAGACAAC-3′
	Reverse: 5′-CCCGACACACAGTAAGCATTC-3′
IL-1β	Forward: 5′-TTGACGGACCCCAAAAGATG-3′
	Reverse: 5′-AGAAGGTGCTCATGTCCTCA-3′
TNF-α	Forward: 5′-TCTCATCAGTTCTATGGCCC-3′
	Reverse: 5′-GGGAGTAGACAAGGTACAAC-3′
MCP-1	Forward: 5′-TTAAAAACCTGGATCGGAACCAA-3′
	Reverse: 5′-GCATTAGCTTCAGATTTACGGGT-3′
β-actin	Forward: 5′-GTGGGCCGCTCTAGGCACCAA-3′
	Reverse: 5′-CTCTTTGATGTCACGCACGATTTC-3′

HMGB1, high-mobility-group box 1; RAGE, receptor for advanced glycation end products; MCP-1, monocyte chemoattractant protein-1.